| Autor: |
Xin, Li, Ning-chen, Li, Qiang, Ding, Song-liang, Cai, Hong-xu, Huo, Shao-yan, Chen, Xiao-jian, Gu, Shi-ping, Chen, Yan-qun, Na |
| Rok vydání: |
2006 |
| Předmět: |
|
| Zdroj: |
Zhonghua nan ke xue = National journal of andrology. 12(3) |
| ISSN: |
1009-3591 |
| Popis: |
To study the efficacy and safety of alpha1 adrenoceptor antagonist Naftopidil in the treatment of chronic non-bacterial prostatitis.An opened, self-controlled, multicentral clinical trial was conducted. One hundred and six cases of patients who had been diagnosed as chronic non-bacterial prostatitis (NBP) were treated with Naftopidil (25 mg once a day) for 4 weeks. The efficacy was evaluated by the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the WBC in the examination of prostatic secretion (EPS) after the treatment.After 4 weeks therapy, 105 cases were evaluable. After treatment, NIH-CPSI total score were averagely decreased 12.0 points (P0.001), symptom score 7.9 points (P0.001) and QOL score 4.1 points (P0.001). There was a statistically significant difference in WBC count ([(15.2 +/- 15.1)/HP vs (9.5 +/- 12.0)/HP, P0.01] and max flow rate(MFR) [(19.2 +/- 4.8) ml/s vs (22.7 +/- 4.9) ml/s, P0.01]. The total effective rate were 84.8% in the whole group. The clinical adverse rate was 3.81%, including 3 cases of mild dizziness and 1 case of mild inappetence.alpha1 adrenoceptor antagonist Naftopidil is effective and safe for the treatment of chronic non-bacterial prostatitis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
